The cost effectiveness of zoledronic acid 5 mg for the management of postmenopausal osteoporosis in women with prior fractures: evidence from Finland, Norway and the Netherlands.

Journal of medical economics

Volumn 14, Issue 1, 2011, Pages 53-64

  Akehurst, R ^a   Brereton, N ^b   Ariely, R ^b   Lusa, T ^b   Groot, M ^b   Foss, P ^b   Boonen, S ^b  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT; IMIDAZOLE DERIVATIVE; ZOLEDRONIC ACID;

AGED; ARTICLE; BONE DENSITY; COMPUTER SIMULATION; COST BENEFIT ANALYSIS; DRUG EFFECT; ECONOMICS; FEMALE; FINLAND; FRACTURE; HUMAN; MIDDLE AGED; NETHERLANDS; NORWAY; POSTMENOPAUSE OSTEOPOROSIS; QUALITY ADJUSTED LIFE YEAR; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; COMPUTER SIMULATION; COST-BENEFIT ANALYSIS; DIPHOSPHONATES; FEMALE; FINLAND; FRACTURES, BONE; HUMANS; IMIDAZOLES; MIDDLE AGED; NETHERLANDS; NORWAY; OSTEOPOROSIS, POSTMENOPAUSAL; QUALITY-ADJUSTED LIFE YEARS; TREATMENT OUTCOME;

EID: 84863949972     PISSN: None     EISSN: 1941837X     Source Type: Journal    
DOI: 10.3111/13696998.2010.545563     Document Type: Article

References (0)